Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer

29 Oct 2021

Abstract excerpt

ARID1A is a key component of the SWI/SNF chromatin remodeling complexes which is important for the maintaining of biological processes of cells. Recent studies had uncovered the potential role of ARID1A alterations or expression loss in the therapeutic sensitivity of cancers, but the studies in this field requires to be further summarized and discussed. Therefore, we proposed a series of mechanisms related to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34715776
DOI: 10.1186/s10020-021-00400-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancerPMID 34715776Read ↗

Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiencySemantic proximity Read ↗

ARID1A is downregulated in non-small cell lung cancer and regulates cell proliferation and apoptosisSemantic proximity Read ↗

ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.Semantic proximity Read ↗

ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.Semantic proximity Read ↗

Targeting ARID1A mutations in cancer.Semantic proximity Read ↗

Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis.Semantic proximity Read ↗

Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.Semantic proximity Read ↗

[Tumor suppressor role of chromatin-remodeling factor ARID1A].Semantic proximity Read ↗

Remodeling of the ARID1A tumor suppressor.Semantic proximity Read ↗

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic TargetSemantic proximity Read ↗

Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.